Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 41 | ECE2016 | Next issue

18th European Congress of Endocrinology

Symposia

An update on hyperparathyroidism

ea0041s21.1 | An update on hyperparathyroidism | ECE2016

Primary hyperparathyroidism: what is new?

Schalin-Jantti Camilla

Primary hyperparathyroidism (PHPT) is a common endocrine disorder, with a prevalence of 1–4 per 1000, that increases to 21 per 1000 in age groups 55–75 years. PHPT may be cured in only one way: by surgical excision of the abnormal parathyroid tissue, which in ~85% of patients is due to a parathyroid adenoma. Double adenomas are found in ~4% of cases and parathyroid carcinoma in 1%. There is consensus that patients with markedly increased serum calcium concentrations,...

ea0041s21.2 | An update on hyperparathyroidism | ECE2016

Hyperparathyroidism, hypertension and hyperaldosteronism

Asbach Evelyn

Primary aldosteronism (PA) is the most frequent cause of endocrine arterial hypertension. PA is known to cause a higher cardiovascular morbidity, which is reduced by specific therapy of PA. Numerous studies suggest that mineralocorticoid excess may influence mineral homeostasis. On the other side, parathyroid hormone excess has been linked to cardiovascular disease. Increasing evidence supports a bidirectional interaction between aldosterone and PTH which might lead to a highe...

ea0041s21.3 | An update on hyperparathyroidism | ECE2016

What is new in imaging and surgery for hyperparathyroidism

Hocevar Marko

During last few decades primary hyperparathyroidism (PHP) evolved from the disease of ‘bones, moans, stones and groans’ to a disorder that is most commonly asymptomatic and incidentally diagnosed with increasing biochemical screening. At the same time different localization studies of the abnormal parathyroid gland(s) emerged. Because PHP is caused in more than 85% of patients with a single gland adenoma which can be reliably localized preoperatively, there has been ...